Allergic asthma is one of the most common asthma phenotypes and is characterized by chronic airway inflammation, wheezing, cough, dyspnea, and airway hyperresponsiveness triggered by allergen exposure. It often begins in childhood and commonly overlaps with other allergic comorbidities, including atopic dermatitis and allergic rhinitis. Current evidence supports a central role for allergen-driven airway inflammation arising from genetic and environmental interactions.
Allergic asthma affects a large global patient population and remains a major area of therapeutic interest, particularly in type 2 inflammation, eosinophilic disease biology, biologics development, and upstream cytokine pathway intervention. In addition to established corticosteroids and bronchodilator-based regimens, current clinical development continues to expand around anti-IgE, anti-IL-5/IL-5R, anti-IL-4Rα, anti-TSLP, JAK-pathway modulation, and emerging targeted protein degradation approaches.
The pathogenesis of allergic asthma is typically described in two linked phases: an early sensitization phase and a later effector phase. During sensitization, allergens crossing a disrupted epithelial barrier are captured by dendritic cells and presented to T cells, promoting type 2-skewed immunity and allergen-specific IgE production. In the effector phase, epithelial alarmins and cytokines such as TSLP, IL-33, IL-25, and GM-CSF amplify downstream immune responses, driving recruitment and activation of Th2 cells, ILC2s, eosinophils, and other inflammatory populations. These processes contribute to mucus production, airway inflammation, bronchial injury, and airway narrowing.
Because allergic asthma is strongly shaped by epithelial-immune cross-talk, eosinophilic inflammation, and treatment-responsive airway pathology, well-controlled in vivo models remain important for pharmacology studies and mechanism-oriented evaluation.
Accelerate your respiratory drug discovery with Cyagen’s comprehensively validated preclinical asthma platforms. We offer robust acute and chronic in vivo models—including classical OVA-induced and clinically relevant HDM-induced allergic asthma—tailored to accurately replicate human airway hyperresponsiveness (AHR), eosinophilic infiltration, and airway remodeling. From customized induction protocols to multidimensional pharmacological evaluations, our end-to-end CRO services provide the reproducible data you need to confidently advance your novel therapeutics.
| Model | Mouse Platform | Application | Action |
|---|---|---|---|
| OVA-induced asthma model | BALB/c mice | Classical allergic asthma studies and corticosteroid efficacy evaluation | |
| OVA-induced asthma model | huIL-4 & IL-4Rα mice | IL-4/IL-13-pathway-targeted pharmacology studies | |
| HDM-induced asthma model | BALB/c mice | Natural allergen-induced asthma model and drug efficacy evaluation | |
| HDM-induced asthma model | huIL-4 & IL-4Rα mice | Allergen-relevant airway inflammation studies |
| Catalog Number | Name | Base Strain | Research Application | Action |
|---|---|---|---|---|
| {{ value.product_num || "--" }} | {{ value.product_name || "--" }} | {{ value.product_strain || "--" }} |
|
+
|
We offer diverse delivery pathways to ensure precise drug exposure and disease induction:
- Systemic Intervention: Expert intraperitoneal (i.p.) dosing for systemic evaluation of small molecules and biologics.
- Localized Induction: Controlled nebulized allergen challenge or intranasal (i.n.) / intratracheal (i.t.) administration to induce localized and reproducible airway inflammation.
- Tailored Regimens: Flexible dosing frequencies designed to match the pharmacokinetics of your specific therapeutic candidate.
| Analysis Category | Specific Services | Key Applications & Targets in Asthma Research |
|---|---|---|
| BALF Immune Cell Profiling | Flow cytometry | Supports characterization of airway inflammatory burden, eosinophilic inflammation, and treatment-associated changes in BALF immune-cell composition in OVA- and HDM-induced asthma models |
| Serological Biomarker Assessment | ELISA | Enables evaluation of allergen-specific humoral responses, sensitization status, and pharmacodynamic effects on IgE-associated type 2 immune pathways |
| Pulmonary Histopathology | H&E staining and pathology scoring | Provides tissue-level assessment of airway inflammation, bronchial injury, mucus exudation, and overall disease severity |
| Inflammatory Phenotype Characterization | Cellular profiling + pathology correlation | Supports discrimination of eosinophilic, neutrophilic, and mixed inflammatory phenotypes across different asthma induction systems |
| Pharmacodynamic Response Evaluation | Multi-endpoint efficacy analysis | Supports preclinical efficacy assessment of corticosteroids, anti-type 2 inflammation therapies, and other mechanism-based asthma therapeutics |
| Mechanism-Oriented Readout Integration | Integrated data interpretation | Facilitates translational evaluation of interventions targeting IL-4/IL-13 signaling, eosinophil-associated inflammation, and broader type 2 airway inflammatory pathways |
- {{v2}}
- {{item}}
